The role of PET imaging probes for early monitoring the response to tamoxifen therapy in a xenograft nude mouse model of ER-positive breast cancer: comparison of $^{18}$F-FDG, $^{18}$F-FES, and $^{18}$F-FLT

Bin Zhang$^1$, Jiajia Dong$^1$, Zhenxin Wang$^2$, Qian Xiong$^2$, Shengming Deng$^1$

Departments of $^1$Nuclear Medicine, $^2$Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

Received March 14, 2018; Accepted November 12, 2018; Epub April 15, 2019; Published April 30, 2019

Abstract: Aim: In the present study, the possibility of using $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG), $^{18}$F-fluoro-17β-estradiol ($^{18}$F-FES), and 3′-deoxy-3′-$^{18}$F-fluorothymidine ($^{18}$F-FLT) to monitor the response to tamoxifen therapy was assessed as early as 3 days in a mouse xenograft model of estrogen receptor-positive (ER+) breast cancer. Materials and Methods: Nude mice bearing ER+ human breast cancer MCF-7 xenografts were treated with vehicle or tamoxifen. Micro-PET imaging with $^{18}$F-FDG, $^{18}$F-FLT, and $^{18}$F-FES was performed prior to and 3 days after treatment. Histopathologic analyses, including hematoxylin and eosin staining (H&E) and immunohistochemical studies (ERα, ERβ, GLUT1, Ki-67, and PCNA), were performed. Results: $^{18}$F-FLT and $^{18}$F-FES uptake was decreased on day 3 after tamoxifen treatment ($P < 0.05$), while $^{18}$F-FDG uptake showed no significant decrease ($P > 0.05$). Immunohistochemical analysis of tumor samples indicated that staining of ERα, GLUT1, Ki-67, and PCNA was decreased in the tamoxifen-treated group compared with the vehicle-treated group ($P < 0.05$). However, no noticeable difference of ERβ staining was observed in tumor cells between vehicle-treated and tamoxifen-treated groups ($P = 0.471$). Peri-necrotic GLUT1 expression was particularly apparent near the necrotic area of tamoxifen-treated tumors. Conclusion: $^{18}$F-FES and $^{18}$F-FLT are superior to $^{18}$F-FDG as PET imaging probes for monitoring the response to tamoxifen treatment as early as 3 days in ER+ breast cancer. Peri-necrotic GLUT1 expression might be one of the reasons why $^{18}$F-FDG PET could not early evaluate the response to tamoxifen therapy. $^{18}$F-FES PET could reliably assess down-regulation of ERα caused by tamoxifen treatment.

Keywords: $^{18}$F-FES, $^{18}$F-FLT, $^{18}$F-FDG, tamoxifen, breast cancer, response evaluation

Introduction

As the most common malignant tumor in females, breast cancer alone accounts for 30% of all newly diagnosed cancer cases among women in USA [1]. Hormone receptor positive (HR+), defined as either estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) tumors account for approximately 70-80% of breast cancers [2].

Endocrine therapy remains one of the mainstream treatments for selected patients with ER+ breast cancer. Tamoxifen, as an estrogen modulator, has been widely used in the treatment of ER+ breast cancer since 1977. Although the clinical benefit of tamoxifen is prominent, many patients with ER+ breast cancer have experienced resistance or other adverse side effects following the tamoxifen therapy. Therefore, it is urgently necessary to develop accurate methodologies for an early evaluation of response at an early time point, by which patients without good response can be switched to more effective alternative treatments early during the course of tamoxifen administration.

In recent decades, positron emission tomography (PET) has become the main technique for molecular imaging. PET permits non-invasive visualization and quantification of various biological processes, which are modulated during therapy of breast cancer, including metabolism, receptor density, cell proliferation, and up-
PET imaging probes for early monitoring the response to tamoxifen therapy

take of therapeutic agents [3]. 18F-fluorodeoxyglucose (18F-FDG) is the most widely used radiotracer for diagnosis, staging, and post-treatment evaluation of cancer. However, 18F-FDG is not strictly tumor-specific, and false-positive results may arise secondary to uptake in inflammatory cells and granulation tissue [4]. 18F-fluoro-17β-estradiol (18F-FES) is emerging as a specific ER-targeted molecular probe for evaluation of ER expression in breast cancer. Some studies have shown that 18F-FES PET can be used to detect ER+ breast cancer lesions and monitor treatment response [5, 6]. 3'-Deoxy-3'-18F-fluorothymidine (18F-FLT) is another PET tracer which reflects proliferative activity in cancer lesions. 18F-FLT crosses the cell membrane and becomes phosphorylated by thymidine kinase 1 (TK-1) into a highly charged product, which is intracellularly trapped and can be imaged using PET. In addition, some studies have reported that 18F-FLT PET imaging can be used to evaluate response to treatment in patients with cancer [7, 8]. It remains unclear which type of radiotracers can be used to monitor the early response to tamoxifen treatment in ER+ breast cancer. Therefore, the goal of this study was to assess the possibility of using 18F-FDG, 18F-FES, and 18F-FLT to monitor the response to tamoxifen treatment as early as 3 days in breast cancer with a mouse xenograft model of ER+ breast cancer. Additionally, immunohistochemical (IHC) analyses of ERα, ERβ, glucose transporter type 1 (GLUT1), Ki-67, and proliferating cell nuclear antigen (PCNA) were performed to investigate the relationship between the underlying biology and the imaging parameters.

Materials and methods

Cell culture

The human breast cancer cell line MCF-7 was purchased from the Shanghai Cell Bank of the Chinese Academy of Science. Cells were cultured in RPMI 1640 medium (Gibco, Rockville, MD, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Rockville, MD, USA) and 1% penicillin/streptomycin at 37°C in a humidified atmosphere containing 5% CO₂.

Animal tumor model

Female athymic nude mice (age, 3-4 weeks) were purchased from the Shanghai Experimental Animal Center (Shanghai, China) and bred in filter-top cages under specific pathogen-free conditions. The MCF-7 model was established through subcutaneous injections of 1 × 10⁷ cells in 200 μL of phosphate-buffered saline (PBS) into the subcutaneous tissue of the right axillary fossa. Mice were subcutaneously injected with 0.2 mL 17β-estradiol (0.15 mg/mL) around the tumor once daily to promote the tumor growth. Tumor volumes were estimated using the formula as follows: 0.5 × length × width². Tamoxifen was administered when the tumor volume reached ~50 mm³ (3-4 weeks after inoculation).

The mice were randomly and evenly assigned into four groups (n = 5 per group). Mice were treated with vehicle (ethanol in normal saline) in the control group. Within the groups receiving tamoxifen treatment, an oral dose of 0.2 mg tamoxifen (Sigma) was intra-gastrically administrated once daily for 3 days.

This study was carried out in accordance with the guidelines of the Institutional Animal Care and Use Committee at the First Affiliated Hospital of Soochow University, and animal-related protocols were approved by the Animal Ethics Committee of the First Affiliated Hospital of Soochow University.

Micro-PET imaging and quantitative analysis

Micro-PET scans and image analysis were performed on day 0 prior to the treatment (baseline) and day 3 after treatment using an Inveon micro-PET scanner (Siemens Medical Solutions).

MCF-7 tumor-bearing mice were injected with 3.7 MBq (100 µCi) of 18F-FDG, 18F-FES, or 18F-FLT via tail vein under isoflurane-induced anesthesia. For 18F-FDG scans, mice were fasted for 8 hours before tracer injection. Subsequently, 20-minute static scans were acquired at 1 hour after injection. During the scanning period, mice were maintained under isoflurane-induced anesthesia and positioned in the center PET ring field of view.

The images were reconstructed using the 2-dimensional ordered subset expectation maximization (OSEM) algorithm, and no attenuation correction was applied. Regions of interest (ROIs) were drawn over the tumor using ASI Pro
A semi-quantitative method was used for scoring ERα+ and ERβ+ areas as described by Peng J et al. [9]. The classes of 0-5%, 5-25%, 25-50%, 50-75%, and > 75% positively stained cells were assigned semi-quantitative scores of 0, 1, 2, 3, and 4, respectively. The intensity was scored according to the following criteria: (0) negative staining; (1) weak staining; (2) moderate staining; and (3) strong staining. The final IHC score was generated by multiplying the staining intensity score by the percentage score.

It was impossible to quantify GLUT1 immunostaining by grading the proportion of cells because staining of the tumor was diffuse in most specimens. Therefore, GLUT1 was scored according to intensity only.

IHC staining for Ki-67 and PCNA was performed to evaluate the proliferation of tumor cells. The brownish nuclei were selected, and the number of Ki-67+ and PCNA+ tumor cells was counted. The immunosignal index was calculated by dividing the number of positively stained cells by the number of whole tumor cells.

Statistical analysis

Quantitative data are expressed as mean ± standard deviation (SD). Student’s t-test (two-tailed) was applied to determine statistical significance between experimental and control groups using IBM SPSS 19.0 software (SPSS Inc. Chicago, IL, USA). P values < 0.05 were considered as statistically significant.

Results

Micro-PET images

When initial micro-PET imaging was performed, the average tumor volume reached 60.06 ± 4.39 mm³. Figure 1A illustrates that significant uptake was clearly visualized in tumors as well as in bladders in the case of all micro-PET tracers. ¹⁸F-FDG showed physiologically high uptake in the heart and brain. No statistically significant difference of ¹⁸F-FDG uptake was observed between day 3 after tamoxifen treatment and baseline, with the SUV_{max} of 1.12 ± 0.16 and 1.05 ± 0.11, respectively (P = 0.378).

The tumor lesion had a good uptake of ¹⁸F-FLT. Significant uptake of ¹⁸F-FLT was also visual-
PET imaging probes for early monitoring the response to tamoxifen therapy

Figure 1. Coronal PET images of MCF-7 human breast cancer xenograft in mice treated with tamoxifen. Dotted circles indicated the tumor regions. Representative images of $^{18}$F-FDG (A), $^{18}$F-FLT (B) and $^{18}$F-FES (C) in xenograft-bearing mice on days 0 and 3 of treatment are shown.

Figure 2. Histopathologic specimens with H&E staining. Microscope images (magnification × 200) of the vehicle-treated (A) and tamoxifen-treated (B) groups are shown.

High $^{18}$F-FES uptake was visualized in tumors as well as in the kidney, spleen and intestine. Quantitative image analysis showed notable differences ($\Delta$SUV$_{max} = 0.13 \pm 0.11$) between the $^{18}$F-FLT uptake of the pre-therapeutic tumors (SUV$_{max} = 0.85 \pm 0.09$) and the tamoxifen-treated tumors (SUV$_{max} = 0.72 \pm 0.08$, $P = 0.039$, Figure 1B).
gallbladder and bowel, which was consistent with hepatobiliary excretion of $^{18}$F-FES. Quantification radioactivity analysis showed a significantly decreased $^{18}$F-FES uptake ($\Delta \text{SUV}_{\text{max}} = 0.32 \pm 0.03$) in the MCF-7 xenograft after the treatment ($\text{SUV}_{\text{max}} = 0.32 \pm 0.09$) compared with baseline $^{18}$F-FES uptake ($\text{SUV}_{\text{max}} = 0.64 \pm 0.12$, Figure 1C).

Histopathologic findings

Different characteristics of tumor apoptosis/necrosis were observed between the two groups by H&E staining of tumor specimens (Figure 2). Actively mitotic tumor cells were abundant in the vehicle-treated group, whereas they were sparse in the tamoxifen group. Moreover, H&E staining indicated that extensive areas of tumor necrosis were present in tamoxifen-treated mice.

IHC analysis

Cytoplasmic immunoreaction of ER$\alpha$ and nuclear immunoreaction of ER$\beta$ were detected in tumor cells. IHC analysis revealed a significantly lower IHC score of ER$\alpha$ in the treatment group compared with the control group (9.60 ± 1.14 vs. 11.00 ± 0.71, respectively; $P = 0.048$). However, no noticeable difference of ER$\beta$ staining was observed in tumor cells between vehicle-treated and tamoxifen-treated groups (10.80 ± 0.84 vs. 11.20 ± 0.84, respectively; $P = 0.471$) (Figure 3).

For GLUT1, a very diffuse staining of the entire tumor cell was observed. Moreover, a statistically significant difference in the IHC score of GLUT1 between the vehicle-treated group and the tamoxifen-treated group (2.72 ± 0.16 vs. 2.48 ± 0.13, respectively; $P = 0.034$) was observed. Furthermore, peri-necrotic GLUT1 expression was particularly apparent near the necrotic area of tamoxifen-treated tumors (Figure 4).

Immunostaining for Ki67 and PCNA was present at the nuclear level. Microscopic examination of tumor xenograft sections showed a decreased immunoreactivity for Ki67 (19.60 ± 1.82 vs. 26.20 ± 2.59, respectively; $P = 0.002$)
Discussion

In clinical settings, early response monitoring would greatly benefit management of patients receiving treatment, which assures continu-
ance of effective therapy in patients with responsive tumors or avoids the use of expensive, toxic and ineffective treatment in those patients with unresponsive tumors. Recently, an increasing number of studies have reported the utilization of PET in the treatment evaluation of different cancers at very early time points [10-12]. According to these results, the best radiotracer and timing for early evaluation may depend on the drugs used and the type of disease [13]. Several investigators have recently used PET to evaluate treatment response of breast cancer in animal models. However, in those studies PET is performed at later times than our study. Moreover, no MCF-7 cell line or tamoxifen has been used, no different radiotracers have been compared, and no comprehensive IHC examination of ERα, ERβ, GLUT1, Ki-67, and PCNA has been performed [14-17]. To the best of our knowledge, this is the first study to have evaluated the efficiency of $^{18}$F-FDG, $^{18}$F-FES, and $^{18}$F-FLT in monitoring the response to tamoxifen treatment as early as 3 days in an animal model of breast cancer.

In this study, it was impossible to assess the therapy efficacy with $^{18}$F-FDG in the early phase because there was no significant difference in $^{18}$F-FDG uptake by breast tumor between the tamoxifen-treated and vehicle-treated groups on day 3. As a glucose analogue, $^{18}$F-FDG enters tumor cells via glucose transporters. Among these glucose transporters, GLUT1 is considered to largely determine $^{18}$F-FDG uptake in cancer [18]. However, there is a controversy surrounding the correlation between GLUT1 and $^{18}$F-FDG in breast cancer. In some studies [19, 20], strong correlation between GLUT1 and $^{18}$F-FDG

Figure 4. IHC staining of GLUT1 expression in representative tumor sections. Staining for GLUT1 in tumors is shown for the vehicle-treated group (A) and the tamoxifen-treated group (B). Magnification × 200. GLUT1 expression also appeared in peri-necrotic areas near tamoxifen-treated tumors (C and D). Magnification × 20. Expression of GLUT1 for the vehicle-treated and tamoxifen-treated groups (E) is summarized. A significant difference of GLUT1 expression was found between tamoxifen-treated and vehicle-treated groups (P < 0.05). Columns, mean; bars, SE.

and PCNA (61.40 ± 3.91 vs. 70.80 ± 5.26, respectively; P = 0.013) in the tamoxifen-treated group compared with the vehicle-treated group (Figure 5).
uptake has been noted, whereas such association is not found in other studies [21, 22]. Here, different trends were observed in changes of $^{18}$F-FDG uptake and GLUT1 expression in breast cancer. Aliaga et al. [25] have also observed that the uptake of $^{18}$F-FDG in ER+ breast cancer can significantly vary within the first 2 weeks after the initiation of the therapy, and the eventual response can be underestimated or overestimated using $^{18}$F-FDG. Therefore, the underlying mechanism should be further investigated.

$^{18}$F-FLT PET has often been studied in the detection of early biological response following anticancer treatment in a wide range of cancers, including breast cancer, in an animal model [26-28]. In general, these studies have indicated that $^{18}$F-FLT PET is sensitive to early molecular changes in xenografts. In line with these studies, our findings suggested that $^{18}$F-FLT PET could detect a significant change as early as 3 days after tamoxifen treatment. $^{18}$F-FLT has been proposed as an imaging biomarker of proliferation because it is phosphorylated by TK-1 and then trapped inside the cell by entering the thymidine salvage pathway of DNA synthesis without incorporation into the DNA molecule. PCNA is an auxiliary protein necessary for DNA synthesis. As PCNA expression is well correlated with DNA synthesis, it has been extensively used as a marker for evaluation of cell proliferation. As a human nuclear protein, the Ki-67 antigen is expressed only in the proliferative phase of the cell cycle, and it is therefore considered to be a reliable proliferative marker. This study assessed expression of both Ki-67 and PCNA to explore the correlation between $^{18}$F-FLT
PET imaging probes for early monitoring the response to tamoxifen therapy

uptake and cell proliferation. Expression of both Ki-67 and PCNA showed a similar decreasing trend with \(^{18}\)F-FLT uptake in tamoxifen-treated tumors. Other investigators have similarly shown such good correlation between \(^{18}\)F-FLT uptake and expression of Ki-67 and PCNA [29, 30].

In recent years, \(^{18}\)F-FES has emerged as a promising predictive biomarker to help identify patients who are likely to benefit from endocrine therapy since its uptake is strongly correlated with the ER expression [31]. However, there are only a few studies about early monitoring of the response to endocrine therapy in breast cancer [15, 32]. In these studies, significant changes in \(^{18}\)F-FES SUV have been found early after endocrine therapy, which is comparable with our findings. Moreover, our data show that \(^{18}\)F-FES is superior to \(^{18}\)F-FLT and \(^{18}\)F-FDG as a PET imaging probe in early evaluation of response to tamoxifen therapy in ER+ breast cancer since \(^{18}\)F-FES uptake exhibited a more significant decrease in the tamoxifen-treated group on day 3 after treatment.

IHC analysis was also performed for ER\(\alpha\) and ER\(\beta\) to explore the relationship between \(^{18}\)F-FES uptake and ER expression. ER\(\alpha\) has been extensively studied as a binding target for both diagnostic and therapeutic agents, while the role of ER\(\beta\) is not fully understood and has not yet been investigated in clinical trials of breast cancer treatment [32]. IHC analysis revealed a significantly decreased ER\(\alpha\) expression in the tamoxifen-treated group. However, no noticeable difference of ER\(\beta\) staining was observed in tumor cells between vehicle-treated and tamoxifen-treated groups. As is known, \(^{18}\)F-FES selectively binds to ER\(\alpha\), and its affinity for ER\(\alpha\) is 6.3 times higher than that for ER\(\beta\). Moreover, ER\(\alpha\) is a well-known target for endocrine therapy with the selective ER modulator tamoxifen [33]. Therefore, this study confirmed that \(^{18}\)F-FES could be used for early and precise evaluation of the efficacy of tamoxifen in a xenograft nude mouse model of ER+ breast cancer.

However, there are some potential limitations in our present study. First, observation was only performed at one time point. It was possible that changes in uptake of radiotracers were missed. A regular time point (day 3) was selected in this study since such time point is widely adopted and early enough for clinical decisions. Second, only one model of breast cancer and one cell line were used in the present study. Therefore, it is necessary to validate these findings through a prospective clinical trial in the future.

Conclusions

\(^{18}\)F-FES and \(^{18}\)F-FLT are superior to \(^{18}\)F-FDG as PET imaging probes for monitoring the response to tamoxifen treatment as early as 3 days in ER+ breast cancer. Peri-necrotic GLUT1 expression might be one of the reasons why \(^{18}\)F-FDG PET could not early evaluate the response to tamoxifen therapy. Collectively, \(^{18}\)F-FES PET could reliably assess the tamoxifen-induced down-regulation of ER\(\alpha\).

Acknowledgements

This work was financially supported by the National Natural Science Foundation of China (No. 81601522), the Natural Science Foundation of Jiangsu Province (No. BK20160348), the Medical Youth Talent Project of Jiangsu Province (No. QNRC2016749) and the Science and Technology Project for the Youth of Suzhou (No. kjxw2015004).

Disclosure of conflict of interest

None.

Address correspondence to: Shengming Deng, Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Gusu District, Suzhou 215006, Jiangsu Province, China. Tel: +86-15051510189; E-mail: dshming@163.com

References

PET imaging probes for early monitoring the response to tamoxifen therapy


PET imaging probes for early monitoring the response to tamoxifen therapy


